Sound Biologics is focused on advancing antibody combination therapies to enhance treatment outcomes for cancer, inflammatory, and autoimmune diseases. Their proprietary MabPair™ platform allows for the creation of custom-designed antibody combinations that leverage the synergistic effects of two full antibodies. This innovative approach aims to minimize the risk of tumor escape and drug resistance while also improving the convenience of administration and reducing costs compared to traditional combination therapies. The platform is designed to address the complexities of biological systems involved in disease, recognizing that targeting multiple pathways can lead to more effective therapeutic benefits than monotherapy.

In addition to the MabPair™ platform, Sound Biologics has developed a bispecific technology platform that facilitates the production of stable heterodimeric bispecific antibodies. This technology enables the generation of novel therapeutic candidates that can target multiple molecules simultaneously. One of their leading products, PSB205, is a first-in-class bifunctional therapy that combines anti-PD-1 and anti-CTLA-4 monoclonal antibodies, demonstrating superior efficacy in preclinical studies compared to existing checkpoint inhibitors. This innovative approach not only aims to enhance the anti-tumor response but also seeks to improve patient tolerability, marking a significant advancement in the field of immuno-oncology.

United States

Sound Biologics creates innovative technology to better serve patients through the development of treatments for cancer. We aspire to discover and progress therapies that will impact human health and reduce the cost of biotherapeutics.

Sound Biologics

Company Details